Interax biotech ag

InterAx Biotech AG: Revolutionizing Drug Discovery with Experimental and Computational Pharmacology

InterAx Biotech AG is a leading biotechnology company that specializes in the integration of experimental and computational pharmacology to reveal critical properties of novel GPCR drug candidates. The company's innovative approach to drug discovery has revolutionized the industry, enabling it to develop highly effective drugs that target specific diseases.

Founded in 2017, InterAx Biotech AG has quickly established itself as a leader in the field of drug discovery. The company's team of experienced scientists and researchers are dedicated to developing new drugs that can improve patient outcomes and quality of life.

InterAx Biotech AG's unique approach combines experimental pharmacology with computational modeling techniques. This allows the company to identify potential drug candidates more efficiently than traditional methods, reducing development time and costs while increasing success rates.

The company's proprietary technology platform enables it to screen large numbers of compounds for their ability to interact with G protein-coupled receptors (GPCRs), which are involved in many physiological processes. By identifying compounds that bind selectively to specific GPCRs, InterAx Biotech AG can develop drugs that target specific diseases more effectively.

InterAx Biotech AG also uses computational modeling techniques such as molecular dynamics simulations and machine learning algorithms to predict how potential drug candidates will interact with their targets at an atomic level. This allows the company to optimize lead compounds for potency, selectivity, safety, and other important properties before they enter clinical trials.

The combination of experimental pharmacology and computational modeling has enabled InterAx Biotech AG to develop a pipeline of promising drug candidates across multiple therapeutic areas including oncology, immunology, neurology, cardiovascular disease, metabolic disorders among others.

One example is IA-1B3 - an orally available small molecule inhibitor targeting CXCR4 receptor which plays a key role in tumor growth metastasis formation. IA-1B3 demonstrated potent anti-tumor activity both in vitro and in vivo, and is currently being evaluated in preclinical studies.

InterAx Biotech AG's success is due to its commitment to innovation, collaboration, and excellence. The company works closely with academic institutions, pharmaceutical companies, and other partners to advance drug discovery research. Its team of experts includes scientists with backgrounds in pharmacology, chemistry, biology, bioinformatics among others.

In conclusion, InterAx Biotech AG is a leading biotechnology company that integrates experimental and computational pharmacology to develop highly effective drugs that target specific diseases. Its innovative approach has revolutionized the industry by reducing development time and costs while increasing success rates. With a pipeline of promising drug candidates across multiple therapeutic areas including oncology, immunology among others - InterAx Biotech AG is poised for continued growth as it continues to push the boundaries of drug discovery research.